Merck Buys Sigma-Aldrich for $17B

Two giants merge as the German drug maker acquires the US-based science supply company.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, GERIBETH CIULLOThe German pharmaceutical and chemical company Merck is purchasing Sigma-Aldrich, which supplies a wide swath of lab reagents, for a whopping $17 billion. According to Reuters, the deal contributes to a record-breaking year for transactions in the healthcare industry, “with year-to-date activity in the sector topping $380 billion, well over double the year-ago level, according to Thomson Reuters data.”

Merck has been growing its lab supply side to become one of the biggest companies in the business, having bought EMD Millipore (a.k.a. Merck Millipore), which sells reagents and lab tools, in 2010. “Sigma helps fill in a lot of the missing pieces” for Merck, Ross Muken, a life sciences industry analyst with ISI Group LLC in New York, told The Wall Street Journal. Merck will now sell the range of life science products, from basic science tools and reagents to pharmaceuticals.

According to the Associated Press, Merck CEO Karl-Ludwig Kley said the firm had a “clear commitment” to St. Louis, Missouri, where Sigma-Aldrich is based. According to the news report, “he said it was too early in the integration process to answer a question ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies